IFRX · InflaRx N.V.

This 6-K filing serves as the formal convening notice for InflaRx’s 2026 Annual General Meeting, highlighting governance continuity and strategic flexibility. The re-appointments of all five incumbent directors—including co-founders Riedemann and Guo—signal strong alignment between leadership and long-term R&D execution, particularly critical for a clinical-stage biotech reliant on pipeline progression. The proposed extensions of board authorities over share issuance, pre-emption rights, and share repurchases reflect proactive capital structure management: the buyback authority (up to 10% of issued capital at a capped premium) provides liquidity tools without immediate commitment, while the authorized capital increase enables future equity-based incentives or financings. The introduction of LTIP 2026 replaces prior plans and may support retention amid competitive talent markets, though specific terms (e.g., vesting, metrics) are not disclosed here. The absence of dividend intent remains consistent with the company’s capital-intensive development model and Dutch legal constraints on distributions. As no financial results, material agreements, or regulatory developments are disclosed, the filing’s impact is procedural and forward-looking rather than event-driven.